Lupin has received final approval for its Clobetasol Propionate Lotion, 0.05% from the United States Food and Drug Administration (USFDA) to market a generic version of Galderma Laboratories, L.P.’s Clobex Lotion, 0.05%. Clobex Lotion, 0.05% had US sales of $14.3 million, as per IMS MAT June 2017.
Lupin’s Clobetasol Propionate Lotion, 0.05% is the AB rated generic equivalent of Galderma Laboratories, L.P.’s Clobex Lotion, 0.05%. It is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses, in patients 18 years of age or older.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
